EcoDrugPlus

Kit Proto-Oncogene, Receptor Tyrosine Kinase

Ensembl ID : ENSSTOG00000000752
Gene Symbol: KIT
4 Cross references
265 Possible Orthologues:

Kras Proto-Oncogene, Gtpase

Ensembl ID : ENSSTOG00000009530
Gene Symbol: KRAS
3 Cross references
201 Possible Orthologues:

Lck Proto-Oncogene, Src Family Tyrosine Kinase

Ensembl ID : ENSSTOG00000012070
Gene Symbol: LCK
3 Cross references
120 Possible Orthologues:

Lyn Proto-Oncogene, Src Family Tyrosine Kinase

Ensembl ID : ENSSTOG00000006783
Gene Symbol: LYN
3 Cross references
202 Possible Orthologues:

Malt1 Paracaspase

Ensembl ID : ENSSTOG00000022780
Gene Symbol: MALT1
3 Cross references
195 Possible Orthologues:

Mapk Activated Protein Kinase 2

Ensembl ID : ENSSTOG00000006367
Gene Symbol: MAPKAPK2
4 Cross references
233 Possible Orthologues:

Mapk Activated Protein Kinase 5

Ensembl ID : ENSSTOG00000026731
Gene Symbol: MAPKAPK5
3 Cross references
179 Possible Orthologues:

Mapk Interacting Serine/threonine Kinase 2

Ensembl ID : ENSSTOG00000012438
Gene Symbol: MKNK2
3 Cross references
220 Possible Orthologues:

Mcl1 Apoptosis Regulator, Bcl2 Family Member

Ensembl ID : ENSSTOG00000027465
Gene Symbol: MCL1
3 Cross references
240 Possible Orthologues:

Mdm2 Proto-Oncogene

Ensembl ID : ENSSTOG00000014702
Gene Symbol: MDM2
2 Cross references
233 Possible Orthologues:

Met Proto-Oncogene, Receptor Tyrosine Kinase

Ensembl ID : ENSSTOG00000029241
Gene Symbol: MET
4 Cross references
211 Possible Orthologues:

Mpl Proto-Oncogene, Thrombopoietin Receptor

Ensembl ID : ENSSTOG00000009180
Gene Symbol: MPL
4 Cross references
186 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).